Project Grant R01HL176844
Award Date 9/4/25
Completion Date 6/30/30
Dollars Obligated $756K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $699,296 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of North Carolina at Chapel Hill (UNC-CH) to investigate optimal treatment strategies for patients with chronic limb threatening ischemia (CLTI). The proposed research will leverage data from the NHLBI-sponsored BEST-CLI randomized controlled trial to identify patient characteristics associated with different disease...
- This $188,136 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to develop an Artificial Intelligence-Enabled Echocardiography Interpretation System (AEIS). The principal investigator, Dr. Chieh-Ju Chao, will train with a multidisciplinary mentoring team led by Drs. Bradley Erickson and Fei-Fei Li to advance his skills in visual-linguistic models and large language models. The goal...
- This Project Grant award of $528,179, awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research conducted by the University of Miami to investigate reprogramming of monocytes to improve neovascularization in peripheral arterial disease and critical limb ischemia. The key objectives are to: 1) determine if extracellular vesicles mediate the systemic effects of monocyte reprogramming, and 2) investigate how reduced expression of the...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $410,449 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Leland Stanford Junior University (Stanford University) on August 1, 2025. The funding supports research to develop novel synthetic biology strategies that would enable the quantitative and dynamic regulation of growth factors and cytokines produced from human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs). The goal...
- The U.S. National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), has awarded a $522,695 Project Grant to Kennesaw State University (KSU) to develop and validate a generative AI framework that can efficiently and accurately predict the biomechanical outputs of the bi-ventricular myocardium. The 3-year project aims to enhance personalized diagnosis and treatment of ventricular diseases, such as hypertrophic cardiomyopathy, heart failure,...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $816,472 project grant to the Icahn School of Medicine at Mount Sinai (ISMMS). The grant, awarded on August 1, 2025 and set to conclude on May 31, 2029, aims to enhance cardiovascular risk prediction and treatment response in obstructive sleep apnea (OSA) patients using advanced AI-based transformer models and multi-modal sleep data. The project will...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $443,544 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Dasisimulations LLC, a minority-owned small business located in Dublin, Ohio. The grant supports the development and validation of an innovative, AI-driven software platform to automatically perform complex measurements for pre-planning transcatheter aortic valve replacement (TAVR) procedures. The project aims to (1) develop and validate the...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $144,989 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop, train, and test deep generative models using computed tomography (CT) images to predict lung injury progression and treatment responses in patients with acute respiratory distress syndrome (ARDS). The goal is to leverage artificial intelligence and image...
- This federal Project Grant award, totaling $753,813 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to develop novel machine learning techniques for predicting cardiovascular outcomes in patients with clonal hematopoiesis of indeterminate potential (CHIP). The key goals are to use cardiac MRI imaging and genomic data to: 1) Develop a machine learning model to accurately identify CHIP patients and predict their risk...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $164,127 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Texas Health Science Center at Houston (UTHealth) to develop an artificial intelligence-based facial recognition tool for screening and early detection of heritable thoracic aortic disease (HTAD). The project aims to leverage facial image data from the Montalcino Aortic Consortium's patient registry to build a...